Modeling the Cost‐Effectiveness of a Smoking‐Cessation Program in a Community Pharmacy Practice

Tran, Mongthuong T.; Holdford, David A.; Kennedy, Daniel; Small, Ralph E.

doi:10.1592/phco.22.17.1623.34118

Cited by 44 publications

(38 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant part of the intervention was smoking cessation programmes, either pharmacotherapy 4, 5, 36, 37, 38, 40, 41, 48, 50, 51, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, behavioural therapy 6, 42, 47, 66, 67, 68, 69 or a combination of these 33, 34, 35, 43, 45, 46, 49, 52, 54, 70, 71, 72, 73, 74, 75. Several studies evaluated wider tobacco control interventions 39, 44, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, whereas five studies included both smoking cessation programmes and tobacco control interventions 89, 90, 91, 92, 93.…”

Section: Resultsmentioning

confidence: 99%

“…In total, 23 of 64 studies reported QALY as their main outcome 5, 35, 38, 40, 41, 47, 48, 49, 56, 58, 59, 61, 62, 63, 65, 69, 70, 76, 78, 81, 86, 88, 94, followed by life years (LY) gained ( n = nine of 64) 33, 43, 46, 66, 67, 68, 73, 74, 89 or a combination of these ( n = 12 of 64) 4, 6, 35, 36, 37, 39, 42, 44, 57, 77, 80, 83. Five of 64 studies reported disability adjusted life years (DALY) as their main outcome 60, 82, 90, 91, 92, and only four of 64 (incremental) net benefit 52, 53, 55, 71.…”

Section: Resultsmentioning

confidence: 99%

“…Thirty of 64 studies used a Markov model, 12 of which used a specific type called the benefits of smoking cessation on outcomes (BENESCO) model 4, 5, 36, 37, 48, 56, 57, 58, 59, 61, 62, 65. Decision‐tree models 41, 43, 52, 55, 63, 71, 75, 83, 93, discrete‐event simulations (DES) 45, 54, the chronic disease model (RIVM‐CDM) 44, 81, 88, the tobacco policy model (TPM) 76, 77, the quit benefits model (QBM) 80, the World Health Organization (WHO) model 90, the global health outcomes model (GHO model) 70 and the abstinent‐contingent treatment model (ABT model) 73 were also used. Twelve of 64 studies did not report explicitly the model used, reporting only decision analysis modelling or simulation modelling 39, 50, 51, 66, 69, 72, 74, 78, 86 or limiting the description to only dynamic or static modelling 42, 82, 92.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

et al. 2017

View full text Add to dashboard Cite

AimsTo identify different types of models used in economic evaluations of smoking cessation, analyse the quality of the included models examining their attributes and ascertain their transferability to a new context.MethodsA systematic review of the literature on the economic evaluation of smoking cessation interventions published between 1996 and April 2015, identified via Medline, EMBASE, National Health Service (NHS) Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA). The checklist‐based quality of the included studies and transferability scores was based on the European Network of Health Economic Evaluation Databases (EURONHEED) criteria. Studies that were not in smoking cessation, not original research, not a model‐based economic evaluation, that did not consider adult population and not from a high‐income country were excluded.FindingsAmong the 64 economic evaluations included in the review, the state‐transition Markov model was the most frequently used method (n = 30/64), with quality adjusted life years (QALY) being the most frequently used outcome measure in a life‐time horizon. A small number of the included studies (13 of 64) were eligible for EURONHEED transferability checklist. The overall transferability scores ranged from 0.50 to 0.97, with an average score of 0.75. The average score per section was 0.69 (range = 0.35–0.92). The relative transferability of the studies could not be established due to a limitation present in the EURONHEED method.ConclusionAll existing economic evaluations in smoking cessation lack in one or more key study attributes necessary to be fully transferable to a new context.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Cessation rates obtained in this study compare favorably with those obtained in recent work using pharmacist-led face-to-face counseling sessions (Dent, Harris, & Noonan, 2009). Other research also has shown that pharmacist interventions for smoking cessation are both effective (Dent, Harris, & Noonan, 2007;Sinclair, Bond, & Stead, 2004) and cost-effective (Tran, Holdford, Kennedy, & Small, 2002) in terms of cost per successful quit attempt and cost per life-year saved.…”

Section: Discussionmentioning

confidence: 99%

A tailored intervention to support pharmacy-based counseling for smoking cessation

Bock¹,

Hudmon²,

Christian³

et al. 2010

Nicotine &Amp; Tobacco Research

View full text Add to dashboard Cite

Introduction: Pharmacists are uniquely positioned within the community to provide smoking cessation counseling to their patients. However, pharmacists experience significant barriers to providing counseling, including limited time, reimbursement, and training in counseling techniques. We tested a computer-driven software system, "Exper_Quit" (EQ), that provided individually tailored interventions to patients who smoke and matching tailored reports for pharmacists to help guide cessation counseling. Methods:A two-phase design was used to recruit an observationonly group (OBS; n = 100), followed by participants (n = 200) randomly assigned to receive either EQ-assisted pharmacist counseling or EQ plus 8 weeks of nicotine transdermal patch (EQ+). Both treatment groups were scheduled to receive two follow-up counseling calls from pharmacists.Results: Most participants in the EQ and EQ+ groups reported receiving counseling from a pharmacist, including follow-up calls, while none of the OBS participants reported speaking with the pharmacist about cessation. At 6 months, fewer OBS participants reported a quit attempt (42%) compared with EQ (76%) or EQ+ (65%) participants (p < .02). At 6 months, 7-day point-prevalence abstinence was 28% and 15% among the EQ+ and EQ groups, respectively, compared with 8% among OBS participants (p < .01), and EQ+ participants were twice as likely to be quit than were EQ participants (p < .01).Discussion: A tailored software system can facilitate the delivery of smoking cessation counseling to pharmacy patients. Results suggest that EQ was successful in increasing (a) the delivery of cessation counseling, (b) quit attempts, and (c) quit rates. Pharmacists can play an important role in the effective delivery of smoking cessation counseling.

show abstract

“…12 While the impact of US pharmacists on quit rates is not well established, preliminary findings appear favorable, 13,14 and pharmacists have proven to be cost-effective participants in tobacco cessation programs. 15,16 Research consistently shows that pharmacists are interested in providing cessation assistance; 86% of pharmacists 17 and 96% of pharmacy students 18 believe that the pharmacy profession should be more active in helping patients quit smoking/using tobacco.…”

Section: Introductionmentioning

confidence: 99%

The Role of Academic Pharmacy in Tobacco Cessation and Control

McBane

Corelli

Albano

et al. 2013

American Journal of Pharmaceutical Education

View full text Add to dashboard Cite

Despite decades of public health initiatives, tobacco use remains the leading known preventable cause of death in the United States. Clinicians have a proven, positive effect on patients' ability to quit, and pharmacists are strategically positioned to assist patients with quitting. The American Association of Colleges of Pharmacy recognizes health promotion and disease prevention as a key educational outcome; as such, tobacco cessation education should be a required component of pharmacy curricula to ensure that all pharmacy graduates possess the requisite evidence-based knowledge and skills to intervene with patients who use tobacco. Faculty members teaching tobacco cessation-related content must be knowledgeable and proficient in providing comprehensive cessation counseling, and all preceptors and practicing pharmacists providing direct patient care should screen for tobacco use and provide at least minimal counseling as a routine component of care. Pharmacy organizations should establish policies and resolutions addressing the profession's role in tobacco cessation and control, and the profession should work together to eliminate tobacco sales in all practice settings where pharmacy services are rendered.

show abstract

Modeling the Cost‐Effectiveness of a Smoking‐Cessation Program in a Community Pharmacy Practice

Abstract: This analysis demonstrates that a pharmacist-directed cessation program is a cost-effective alternative to a self-directed quit attempt with respect to payers and society. Additional analyses conducted in community pharmacy practice are necessary to corroborate our results.

Cited by 44 publications

References 22 publications

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

Model‐based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review

A tailored intervention to support pharmacy-based counseling for smoking cessation

The Role of Academic Pharmacy in Tobacco Cessation and Control

Contact Info

Product

Resources

About